MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

Decipher (and other MolDX‑assessed equivalent genomic assays) is covered for men with localized or biochemically recurrent prostate adenocarcinoma without clinical metastasis who have a life expectancy of at least 10 years and are candidates for or considering specified management changes (e.g., active surveillance vs definitive therapy, radiation with/without ADT, post‑prostatectomy decisions). Coverage requires testing of FFPE prostate tissue with ≥0.5 mm linear tumor or a prostate resection specimen, no prior pelvic radiation or ADT before the specimen, and documented intended use of the result to guide treatment per established guidelines; other assays require MolDX technical assessment of analytic and clinical validity.

"Male with localized or biochemically recurrent prostate adenocarcinoma (no clinical evidence of metastasis) and life expectancy >= 10 years who is a candidate for and is considering conservative ma..."